Reply to K. Lu

Affiliations

Comment

Michael J Morris. J Clin Oncol. 2015.

. 2015 Oct 1;33(28):3222-3.

doi: 10.1200/JCO.2015.62.4692. Epub 2015 Jul 27.

No abstract available

Comment on

Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.
Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, De Bono J, Cruz FM, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak DP, Lee SY, Webb IJ, Tejura B, Borgstein N, Dreicer R. Fizazi K, et al. J Clin Oncol. 2015 Mar 1;33(7):723-31. doi: 10.1200/JCO.2014.56.5119. Epub 2015 Jan 26. J Clin Oncol. 2015. PMID: 25624429 Free PMC article. Clinical Trial.
The Negative Is Not So Negative: What Do We Learn From Trials With Orteronel?
Lu K. Lu K. J Clin Oncol. 2015 Oct 1;33(28):3221. doi: 10.1200/JCO.2015.62.3165. Epub 2015 Jul 27. J Clin Oncol. 2015. PMID: 26215959 No abstract available.